I found the field of Pharmacology & Pharmacy very interesting. Saw the article A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species published in 2020.0. SDS of cas: 93-02-7, Reprint Addresses Neamati, N (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.; Sechi, M (corresponding author), Univ Sassari, Dept Chem & Pharm, I-07100 Sassari, Italy.. The CAS is 93-02-7. Through research, I have a further understanding and discovery of 2,5-Dimethoxybenzaldehyde
Redox modulators have been developed as an attractive approach to treat cancer. Herein, we report the synthesis, identification, and biological evaluation of a quinazolinedione reactive oxygen species (ROS) inducer, QD394, with significant cytotoxicity in pancreatic cancer cells. QD394 shows a transcriptomic profile remarkably similar to napabucasin, a cancer stemness inhibitor. Both small molecules inhibit STAT3 phosphorylation, increase cellular ROS, and decrease the GSH/GSSG ratio. Moreover, QD394 causes an iron- and ROS-dependent, GPX4 mediated cell death, suggesting ferroptosis as a major mechanism. Importantly, QD394 decreases the expression of LRPPRC and PNPT1, two proteins involved in mitochondrial RNA catabolic processes and both negatively correlated with the overall survival of pancreatic cancer patients. Pharmacokinetics-guided lead optimization resulted in the derivative QD394-Me, which showed improved plasma stability and reduced toxicity in mice compared to QD394. Overall, QD394 and QD394-Me represent novel ROS-inducing drug-like compounds warranting further development for the treatment of pancreatic cancer.
About 2,5-Dimethoxybenzaldehyde, If you have any questions, you can contact Hu, S; Sechi, M; Singh, PK; Dai, LP; McCann, S; Sun, DX; Ljungman, M; Neamati, N or concate me.. SDS of cas: 93-02-7
Reference:
Isothiazole – Wikipedia,
,Isothiazole – ScienceDirect.com